Camiel Verhamme

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2607281/publications.pdf

Version: 2024-02-01

45 papers

1,638 citations

394390 19 h-index 302107 39 g-index

45 all docs 45 docs citations

45 times ranked 1517 citing authors

#	Article	IF	CITATIONS
1	Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy la. Journal of Neurology, 2004, 251, 1491-1497.	3.6	509
2	Impact of ICU-acquired weakness on post-ICU physical functioning: a follow-up study. Critical Care, 2015, 19, 196.	5.8	137
3	The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain, 2009, 132, 3252-3262.	7.6	136
4	Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Medicine, 2009, 7, 70.	5.5	74
5	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 187-194.	3.1	59
6	Diagnostic accuracy of quantitative neuromuscular ultrasound for the diagnosis of intensive care unit-acquired weakness: a cross-sectional observational study. Annals of Intensive Care, 2017, 7, 40.	4.6	54
7	Muscle imaging in inherited and acquired muscle diseases. European Journal of Neurology, 2016, 23, 688-703.	3.3	51
8	Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology, 2020, 94, e62-e74.	1.1	51
9	Myelin and Axon Pathology in a Long-Term Study of (i>PMP22 < /i>-Overexpressing Mice. Journal of Neuropathology and Experimental Neurology, 2011, 70, 386-398.	1.7	48
10	Corticosteroids in chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, 2018, 265, 2052-2059.	3.6	35
11	Variation in <i>SIPA1L2</i> is correlated with phenotype modification in Charcot– Marie– Tooth disease type 1A. Annals of Neurology, 2019, 85, 316-330.	5. 3	33
12	Early Prediction of Intensive Care Unit–Acquired Weakness Using Easily Available Parameters: A Prospective Observational Study. PLoS ONE, 2014, 9, e111259.	2.5	32
13	Nerve ultrasound. Neurology, 2019, 92, .	1.1	32
14	Nerve ultrasound for diagnosing chronic inflammatory neuropathy. Neurology, 2020, 95, e1745-e1753.	1.1	32
15	Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 2020, 143, 3214-3224.	7.6	30
16	Effects of early and late diabetic neuropathy on sciatic nerve block duration and neurotoxicity in Zucker diabetic fatty rats. British Journal of Anaesthesia, 2015, 114, 319-326.	3.4	28
17	Muscle and nerve inflammation in intensive care unit-acquired weakness: A systematic translational review. Journal of the Neurological Sciences, 2014, 345, 15-25.	0.6	25
18	Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology, 2021, 60, 1784-1792.	1.9	25

#	Article	IF	CITATIONS
19	A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A. Orphanet Journal of Rare Diseases, 2021, 16, 433.	2.7	23
20	Hypermorphic and hypomorphic AARS alleles in patients with CMT2N expand clinical and molecular heterogeneities. Human Molecular Genetics, 2018, 27, 4036-4050.	2.9	22
21	Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study. Journal of Neuromuscular Diseases, 2019, 6, 201-211.	2.6	19
22	Diffusion tensor MRI of the healthy brachial plexus. PLoS ONE, 2018, 13, e0196975.	2.5	17
23	Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. European Journal of Neurology, 2020, 27, 506-513.	3.3	16
24	Expert consensus on the combined investigation of ulnar neuropathy at the elbow using electrodiagnostic tests and nerve ultrasound. Clinical Neurophysiology, 2021, 132, 2274-2281.	1,5	16
25	Expert consensus on the combined investigation of carpal tunnel syndrome with electrodiagnostic tests and neuromuscular ultrasound. Clinical Neurophysiology, 2022, 135, 107-116.	1.5	16
26	Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2018, 23, 49-54.	3.1	15
27	Diffusionâ€prepared neurography of the brachial plexus with a large fieldâ€ofâ€view at 3T. Journal of Magnetic Resonance Imaging, 2016, 43, 644-654.	3.4	14
28	Diagnosis and treatment response in the asymmetric variant of chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System, 2019, 24, 174-179.	3.1	10
29	Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy. Journal of the Neurological Sciences, 2019, 397, 141-145.	0.6	10
30	Assessment of intensive care unitâ€acquired weakness in young and old mice: An E. coli septic peritonitis model. Muscle and Nerve, 2016, 53, 127-133.	2.2	8
31	Efficacy of a physical activity programme combining individualized aerobic exercise and coaching to improve physical fitness in neuromuscular diseases (l'M FINE): study protocol of a randomized controlled trial. BMC Neurology, 2020, 20, 184.	1.8	7
32	Deriving reference values for nerve conduction studies from existing data using mixture model clustering. Clinical Neurophysiology, 2021, 132, 1820-1829.	1,5	7
33	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clinical Neurophysiology, 2022, 138, 231-240.	1.5	7
34	In Patients with an α-Galactosidase A Variant, Small Nerve Fibre Assessment Cannot Confirm a Diagnosis of Fabry Disease. JIMD Reports, 2015, 28, 95-103.	1.5	6
35	Pseudodominant inheritance pattern in a family with CMT2 caused by GDAP1 mutations. Journal of the Peripheral Nervous System, 2017, 22, 464-467.	3.1	6
36	Quantitative magnetic resonance imaging of the brachial plexus shows specific changes in nerve architecture in chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy and motor neuron disease. European Journal of Neurology, 2021, 28, 2716-2726.	3.3	6

#	Article	IF	CITATIONS
37	Ultrasound and MR muscle imaging in new onset idiopathic inflammatory myopathies at diagnosis and after treatment: a comparative pilot study. Rheumatology, 2022, 62, 300-309.	1.9	6
38	Prognostic value of nerve ultrasonography: A prospective multicenter study on the natural history of chronic inflammatory neuropathies. European Journal of Neurology, 2021, 28, 2327-2338.	3. 3	5
39	Muscle weakness in a S. pneumoniae sepsis mouse model. Annals of Translational Medicine, 2019, 7, 9-9.	1.7	4
40	Distal muscle weakness and optic atrophy without central nervous system involvement in a patient with a homozygous missense mutation in the C19ORF12-gene. Clinical Neurology and Neurosurgery, 2021, 206, 106637.	1.4	2
41	No association between systemic complement activation and intensive care unit-acquired weakness. Annals of Translational Medicine, 2018, 6, 115-115.	1.7	2
42	OptimisAtion of Diagnostic Accuracy in idioPathic inflammaTory myopathies (ADAPT study): a protocol for a prospective diagnostic accuracy study of multimodality testing in patients suspected of a treatable idiopathic inflammatory myopathy. BMJ Open, 2021, 11, e053594.	1.9	1
43	Assessment of disability in idiopathic inflammatory myopathy: a call for linearity. Rheumatology, 2022, 61, 3420-3426.	1.9	1
44	Dutch injection versus surgery trial in patients with carpal tunnel syndrome (DISTRICTS): protocol of a randomised controlled trial comparing two treatment strategies. BMJ Open, 2022, 12, e057641.	1.9	1
45	Reply: Age-dependent penetrance among females with X-linked adrenoleukodystrophy. Brain, 2015, 138, e326-e326.	7.6	O